INT1436

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.58
First Reported 1977
Last Reported 2011
Negated 1
Speculated 0
Reported most in Abstract
Documents 41
Total Number 42
Disease Relevance 10.85
Pain Relevance 11.26

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

signal transduction (Pomc) generation of precursor metabolites and energy (Pomc) extracellular space (Pomc)
extracellular region (Pomc) cell-cell signaling (Pomc) cytoplasm (Pomc)
Anatomy Link Frequency
pituitary 28
anterior pituitary 6
Melanocyte 4
AtT20 4
plasma 2
Pomc (Mus musculus)
Pain Link Frequency Relevance Heat
Somatostatin 126 100.00 Very High Very High Very High
noradrenaline 45 100.00 Very High Very High Very High
antagonist 403 99.92 Very High Very High Very High
agonist 247 99.92 Very High Very High Very High
Endogenous opioid 16 99.88 Very High Very High Very High
Pain 13 99.86 Very High Very High Very High
Periaqueductal grey 8 99.60 Very High Very High Very High
Clonidine 16 99.58 Very High Very High Very High
dexamethasone 19 99.46 Very High Very High Very High
narcan 33 99.36 Very High Very High Very High
Disease Link Frequency Relevance Heat
Stress 687 100.00 Very High Very High Very High
Hypopituitarism 44 100.00 Very High Very High Very High
Cancer 257 99.96 Very High Very High Very High
Pituitary Cancer 122 99.96 Very High Very High Very High
Pain 11 99.86 Very High Very High Very High
Urological Neuroanatomy 10 99.60 Very High Very High Very High
Post Operative Pain 8 99.20 Very High Very High Very High
Depression 49 99.16 Very High Very High Very High
Natriuresis 57 98.88 Very High Very High Very High
Disease 69 98.56 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
It was established that the short-acting steroid which the patient was receiving was cleared so rapidly that endogenous ACTH secretion was not inhibited.
Negative_regulation (inhibited) of Localization (secretion) of ACTH
1) Confidence 0.58 Published 1980 Journal Acta Endocrinol. Section Abstract Doc Link 6254306 Disease Relevance 0.32 Pain Relevance 0.18
Administration of D-Trp6-LH-RH in a dose of 25 micrograms/day, 3-18 days after inoculation with the tumor, inhibited the growth of the prolactin (PRL) and ACTH-secreting pituitary tumor 7315a in female Buffalo rats.
Negative_regulation (inhibited) of Localization (secreting) of ACTH in pituitary associated with cancer and pituitary cancer
2) Confidence 0.57 Published 1984 Journal Med Oncol Tumor Pharmacother Section Abstract Doc Link 6242477 Disease Relevance 1.53 Pain Relevance 0.08
The increased pain after suppression of beta-endorphin release by the low dose of dexamethasone suggests that pituitary secretion of immunoreactive beta-endorphin alleviates postoperative pain under these conditions.
Negative_regulation (suppression) of Localization (release) of beta-endorphin in pituitary associated with pain, perioperative pain and dexamethasone
3) Confidence 0.56 Published 1987 Journal Clin. Pharmacol. Ther. Section Abstract Doc Link 2961501 Disease Relevance 0.61 Pain Relevance 0.82
The present study examined this question by evaluating the effects of intravenous placebo or dexamethasone (0.1, 0.32, or 1.0 mg) on suppression of immunoreactive beta-endorphin secretion and development of postoperative pain after the surgical removal of impacted third molars in 48 patients.
Negative_regulation (suppression) of Localization (secretion) of beta-endorphin in molars associated with perioperative pain and dexamethasone
4) Confidence 0.56 Published 1987 Journal Clin. Pharmacol. Ther. Section Abstract Doc Link 2961501 Disease Relevance 0.47 Pain Relevance 0.67
Previous studies have shown that a novel exploratory experience given 1 h prior to training blocks the release of brain beta-endorphin and blocks the memory-enhancing effects of post-training naloxone.
Negative_regulation (blocks) of Localization (release) of beta-endorphin in brain associated with narcan
5) Confidence 0.51 Published 1987 Journal Psychopharmacology (Berl.) Section Abstract Doc Link 3110846 Disease Relevance 0 Pain Relevance 0.40
It was concluded that the increases in serum glucose and corticosterone after clonidine administration were not mediated by central effects but that alpha 2-adrenoceptor agonism by clonidine was responsible for inhibition of hypothalamic noradrenaline neuronal activity and pituitary ACTH release.
Negative_regulation (inhibition) of Localization (release) of ACTH in pituitary associated with noradrenaline and clonidine
6) Confidence 0.50 Published 1985 Journal Eur. J. Pharmacol. Section Abstract Doc Link 2990960 Disease Relevance 0 Pain Relevance 0.74
Various interpretations of the decreased secretion of H-endorphin are discussed.
Negative_regulation (decreased) of Localization (secretion) of H-endorphin
7) Confidence 0.49 Published 1984 Journal Psychopharmacology (Berl.) Section Abstract Doc Link 6427830 Disease Relevance 0.60 Pain Relevance 0.08
It seems likely that endogenous opioids also inhibit the release of a third ACTH secretagogue or promote the secretion of an ACTH release inhibitory factor.
Negative_regulation (inhibit) of Localization (release) of ACTH associated with endogenous opioid
8) Confidence 0.45 Published 1995 Journal Endocrinology Section Abstract Doc Link 7588252 Disease Relevance 0 Pain Relevance 0.39
Propofol inhibits in vitro secretion of beta-endorphin from a mouse pituitary cell line (AtT-20).
Negative_regulation (inhibits) of Localization (secretion) of beta-endorphin in AtT-20
9) Confidence 0.43 Published 2003 Journal Reg Anesth Pain Med Section Abstract Doc Link 12567337 Disease Relevance 0.10 Pain Relevance 0.38
After a meal, the gut releases PYY3–36 into the circulation, which crosses the BBB and reduces food intake by suppressing NPY release and increasing POMC release in the arcuate nucleus [77-80].
Negative_regulation (suppressing) of Localization (release) of POMC in gut
10) Confidence 0.40 Published 2007 Journal Nutr Metab (Lond) Section Body Doc Link PMC2018708 Disease Relevance 0.28 Pain Relevance 0.08
The metabolic clearance rate (MCR) of adrenocorticotropin (ACTH) was estimated after the intravenous infusion of graded rates of the hormone (40-2560 muU/min per 100 g body weight) in rats pretreated with chlorpromazine, morphine, and Nembutal, a preparation which proved effective in blocking endogenous ACTH release.
Negative_regulation (blocking) of Localization (release) of ACTH in body associated with body weight and morphine
11) Confidence 0.38 Published 1977 Journal Can. J. Physiol. Pharmacol. Section Abstract Doc Link 200321 Disease Relevance 0.10 Pain Relevance 0.10
Naloxone had no effect on basal plasma ACTH or corticosterone concentration, but it reduced ACTH secretion in virgin rats 5 min after forced swimming; in pregnant rats naloxone had no such effect.
Negative_regulation (reduced) of Localization (secretion) of ACTH in plasma associated with narcan
12) Confidence 0.35 Published 1998 Journal J. Endocrinol. Section Abstract Doc Link 9771473 Disease Relevance 0.16 Pain Relevance 0.69
Rat pituitary corticotrophs express multiple somatostatin receptors (sst), including sst2 and sst5,49 but treatment of cultured rat corticotrophs with native SS-14 does not result in inhibition of ACTH release.50 However, SS-14 is able to decrease ACTH release when rat pituitary cells are cultured in glucocorticoid-free media.51 Therefore, it can be hypothesized that the presence of glucocorticoids reduces the inhibitory effects of native SS and traditional SS analogs on ACTH release through the down regulation of the SS binding sites.52 A number of studies have indicated that, in the murine AtT-20 cells, sst2 and sst5 are principally involved in the regulation of ACTH release.
Negative_regulation (decrease) of Localization (release) of ACTH in pituitary associated with somatostatin
13) Confidence 0.34 Published 2010 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2963160 Disease Relevance 0.16 Pain Relevance 0.67
Moreover, functional studies in vitro correlated very well with the D2 expression data, and adenomas with high D2 expression responded well to either bromocriptine or the newest dopaminergic cabergoline with acute inhibition of ACTH release by 43% to 60%.


Negative_regulation (inhibition) of Localization (release) of ACTH associated with adenoma
14) Confidence 0.34 Published 2010 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2963160 Disease Relevance 0.32 Pain Relevance 0.06
Pretreatment of rats with this compound causes a significant reduction in ACTH release after restraint stress or lipopolysaccharide (LPS) challenge (Spiga et al. 2009a) and to a heterotypic stressor after repeated restraint (Spiga et al. 2009b) (see Table III).
Negative_regulation (reduction) of Localization (release) of ACTH associated with stress
15) Confidence 0.32 Published 2011 Journal Stress (Amsterdam, Netherlands) Section Body Doc Link PMC3016603 Disease Relevance 0.29 Pain Relevance 0.37
ACTH and corticosterone secretion in response to forced swimming was attenuated in pregnant rats compared to virgin rats, measured at 5 min.
Negative_regulation (attenuated) of Localization (secretion) of ACTH
16) Confidence 0.26 Published 1998 Journal J. Endocrinol. Section Abstract Doc Link 9771473 Disease Relevance 0.17 Pain Relevance 0.66
Rat pituitary corticotrophs express multiple somatostatin receptors (sst), including sst2 and sst5,49 but treatment of cultured rat corticotrophs with native SS-14 does not result in inhibition of ACTH release.50 However, SS-14 is able to decrease ACTH release when rat pituitary cells are cultured in glucocorticoid-free media.51 Therefore, it can be hypothesized that the presence of glucocorticoids reduces the inhibitory effects of native SS and traditional SS analogs on ACTH release through the down regulation of the SS binding sites.52 A number of studies have indicated that, in the murine AtT-20 cells, sst2 and sst5 are principally involved in the regulation of ACTH release.
Negative_regulation (reduces) of Localization (release) of ACTH in pituitary associated with somatostatin
17) Confidence 0.25 Published 2010 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2963160 Disease Relevance 0.15 Pain Relevance 0.68
More recently, it was found that sst5-targeting agonists were more effective than sst2-targeting agonists in inhibiting ACTH release; this could depend on dexamethasone decreasing sst2 but not sst5 expression.
Negative_regulation (inhibiting) of Localization (release) of ACTH associated with agonist and dexamethasone
18) Confidence 0.25 Published 2010 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2963160 Disease Relevance 0.24 Pain Relevance 0.64
As shown in Table II, we find some acute and chronic stressors are not influenced by the loss of the Avpr1b (e.g. acute severe restraint), some have a reduced ACTH response only (e.g. acute forced swimming stress) and some have both a reduced ACTH and CORT response in Avpr1b KOs compared to wild types (e.g. acute and repeated novel environment stress).
Negative_regulation (reduced) of Localization (response) of ACTH associated with stress
19) Confidence 0.24 Published 2011 Journal Stress (Amsterdam, Netherlands) Section Body Doc Link PMC3016603 Disease Relevance 0.74 Pain Relevance 0.03
Treatment of cells with the dopaminergic agonist 2-bromo-alpha-ergocryptine resulted in significant decreases in secretion of alpha-MSH, PCE, and APBE.
Negative_regulation (decreases) of Localization (secretion) of alpha-MSH associated with agonist
20) Confidence 0.23 Published 1989 Journal J. Neurochem. Section Abstract Doc Link 2540280 Disease Relevance 0 Pain Relevance 0.05

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox